Distributes brand-name and generic pharmaceuticals to a wide array of healthcare providers. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $3.3B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 23.3× for every dollar of annual profit — around what a business like this usually costs.
Analysts' average target sits 5% below today's price.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 11% a year on average.
The price action doesn’t yet back an upward turn. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.